Not yet recruiting NCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BTK inhibitor.
- Who it may be relevant to
- Registry conditions: CLL. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
Overview
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Interventions
- Drug BTK inhibitor
patients with treatment naive or R/R CLL who treatment with BTK inhibitor
Primary outcome measures
- Overall Survival [Time frame: up to five years]
Secondary outcome measures (2)
- Time to Next Therapy (TTNT) [Time frame: up to two years]
- Adverse Events [Time frame: up to five years]
Eligibility criteria
Inclusion criteria
- Patients aged ≥18 years old
- Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
- Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
- Prior or current use of BTK inhibitor for ≥3 months
- At least one follow-up was recorded during BTK inhibitor treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06557304 · BTKi-CLL-RWE